NHL Diffuse Large B Cell Lymphoma Forecast and Market Analysis 2018-2034 - CAR-T Therapies will Become the Highest-Selling Class - ResearchAndMarkets.com

DUBLIN--()--The "NHL: Diffuse Large B Cell Lymphoma Forecast and Market Analysis to 2034" drug pipelines has been added to ResearchAndMarkets.com's offering.

Diffuse large B-cell lymphoma (DLBCL) is a form of hematological malignancy that affects B lymphocytes. This cancer is the most common type of non-Hodgkin's lymphoma (NHL), accounting for about one-third of all newly diagnosed cases. The disease occurs predominantly in older people, with a median age of diagnosis around 65 years, and has a slightly higher prevalence in men than in women. DLBCL is categorized as an aggressive form of NHL; after initial onset the cancer advances quickly and can be fatal if left untreated. However, prompt and suitable treatment can lead to cure in more than 50% of cases.

Recent events and opinion

  • CAR-T therapies will become the highest-selling class over the forecast period.
  • The survey of 223 medical oncologists in the US, Japan, and five major EU markets elucidates prescribing trends in DLBCL.
  • Incident cases of the three major subtypes of NHL will increase by at least a quarter over the forecast period.
  • CAR-T therapies Yescarta and Kymriah, as well as Keytruda in PMBCL patients, represent a new era in DLBCL treatment.
  • Several novel mechanisms are in development for DLBCL, signaling a potentially segmented future treatment paradigm.

Key Topics Covered:

FORECAST: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 09 October 2018)

Overview

Recent Forecast Updates

Market Dynamics

Forecast And Future Trends

Market Definition And Methodology

Primary Research Methodology

Bibliography

Product Profile (Late Stage): Bavencio

Product Profile (Late Stage): Blincyto

Product Profile: Keytruda

Product Profile (Late Stage): Kinenza

Product Profil

Disease Background

Methodology

Forecast

Bibliography

Appendix: Additional Sources

MARKETED DRUGS: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 09 October 2018)

Overview

Product Overview

Product Profile: Keytruda

Product Profile: Kymriah

Product Profile: Rituxan

Product Profile: Yescarta

PIPELINE: DIFFUSE LARGE B-CELL LYMPHOMA (Published on 09 October 2018)

Overview

Clinical Pipeline Overview

Target Product Profile

Additional Pharma Intelligence Pipeline Resources

Product Profile (Late Stage): Bavencio

Product Profile (Late Stage): Blincyto

Product Profile (Late Stage): Imbruvica

Product Profile (Late Stage): Kinenza

Product Profile (Late Stage): Mor208

Product Profile (Late Stage): Revlimid

Product Profile (Late Stage): Lisocabtagene Maraleucel

Product Profile (Late Stage): Polatuzumab Vedotin

Product Profile (Late Stage): Selinexor

Product Profile (Late Stage): Ublituximab

Product Profile (Late Stage): Umbralisib

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/2wzkq4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lymphoma Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Lymphoma Drugs